FRESH TRACKS THERAPEUTICS IN (FRTX) Stock Price, Forecast & Analysis
USA - NASDAQ:FRTX - US10802T2042 - Common Stock
FRTX Key Statistics, Chart & Performance
The current stock price of FRTX is 0.79 USD. In the past month the price decreased by -4.76%. In the past year, price decreased by -42.75%.
FRTX Latest News, Press Relases and Analysis
FRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.75 | 413.15B | ||
| AMGN | AMGEN INC | 15.73 | 185.19B | ||
| GILD | GILEAD SCIENCES INC | 15.53 | 157.81B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.09 | 111.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 76.88B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 906.47 | 60.60B | ||
| INSM | INSMED INC | N/A | 42.62B | ||
| NTRA | NATERA INC | N/A | 29.32B | ||
| BIIB | BIOGEN INC | 10.09 | 24.75B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.06 | 21.56B | ||
| INCY | INCYTE CORP | 16.18 | 20.29B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 33.17 | 13.75B |
Related stock screener links
About FRTX
Company Profile
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 13 full-time employees. The firm is engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new chemical entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory, and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Next-Generation Kinase Inhibitors and FRTX-03. FRTX-02 is a potential Oral DYRK1A Inhibitor for the treatment of autoimmune and inflammatory diseases. Its FRTX-10 is a covalent Stimulator of Interferon Genes (STING) inhibitor candidate for the potential treatment of autoimmune, inflammatory, and rare genetic diseases.
Company Info
FRESH TRACKS THERAPEUTICS IN
5777 Central Ave Ste 102
Boulder COLORADO US
Employees: 13
Phone: 17205054755
FRESH TRACKS THERAPEUTICS IN / FRTX FAQ
Can you describe the business of FRESH TRACKS THERAPEUTICS IN?
Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. The company is headquartered in Boulder, Colorado and currently employs 13 full-time employees. The firm is engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new chemical entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory, and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Next-Generation Kinase Inhibitors and FRTX-03. FRTX-02 is a potential Oral DYRK1A Inhibitor for the treatment of autoimmune and inflammatory diseases. Its FRTX-10 is a covalent Stimulator of Interferon Genes (STING) inhibitor candidate for the potential treatment of autoimmune, inflammatory, and rare genetic diseases.
What is the stock price of FRESH TRACKS THERAPEUTICS IN today?
The current stock price of FRTX is 0.79 USD. The price decreased by -2.48% in the last trading session.
Does FRTX stock pay dividends?
FRTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of FRTX stock?
FRTX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for FRTX stock?
7 analysts have analysed FRTX and the average price target is 4.59 USD. This implies a price increase of 481.01% is expected in the next year compared to the current price of 0.79.
Can you provide the growth outlook for FRESH TRACKS THERAPEUTICS IN?
The Revenue of FRESH TRACKS THERAPEUTICS IN (FRTX) is expected to decline by -58.02% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for FRTX stock?
You can find the ownership structure of FRESH TRACKS THERAPEUTICS IN (FRTX) on the Ownership tab.
FRTX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FRTX. When comparing the yearly performance of all stocks, FRTX is a bad performer in the overall market: 89.63% of all stocks are doing better.
FRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FRTX. The financial health of FRTX is average, but there are quite some concerns on its profitability.
FRTX Financial Highlights
Over the last trailing twelve months FRTX reported a non-GAAP Earnings per Share(EPS) of -2.67. The EPS increased by 68.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -68.63% | ||
| ROE | -82.48% | ||
| Debt/Equity | 0 |
FRTX Forecast & Estimates
7 analysts have analysed FRTX and the average price target is 4.59 USD. This implies a price increase of 481.01% is expected in the next year compared to the current price of 0.79.
For the next year, analysts expect an EPS growth of 5.44% and a revenue growth -58.02% for FRTX